SMBCi002-A
General
Cell Line |
|
| hPSCreg name | SMBCi002-A |
| Cite as: | SMBCi002-A (RRID:CVCL_YC54) |
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
|
| Last update | 20th January 2020 |
| User feedback | |
Provider |
|
| Generator | Shandong Medicinal Biotechnology Center (SMBC) |
| Owner | Shandong Medicinal Biotechnology Center (SMBC) |
| Derivation country | China |
External Databases |
|
| BioSamples | SAMEA5945659 |
| Cellosaurus | CVCL_YC54 |
| Wikidata | Q98132699 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | fetal |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Family history | The Donor and her father are patients with clubfoot |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA5945656 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Alternatives to consent are available? | No |
| Is there other documentation provided to the donor for consenting purposes? | No |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent pertain to a specific research project? | Yes |
| Details on restriction to research project | |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Ethics Committee of Shandong Medicinal Biotechnology Center |
| Approval number | SMBC2018-10 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Ethics Committee of Shandong Medicinal Biotechnology Center |
| Approval number | SMBC2018-10 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type |
A cell of fetal origin obtained in an amniotic fluid specimen.
Synonyms
|
| Source cell origin |
The fluid within the amniotic cavity which surrounds and protects the developing embryo. It is initially produced by the amnion and then later by the lungs and kidneys. The amount at term normally varies from 500 to 2000 ml.
Synonyms
|
| Age of donor (at collection) | fetal |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
| Is reprogramming vector detectable? |
Yes |
| Methods used |
PCR
|
| Notes on reprogramming vector detection | The target fragment was verified by PCR in the episomal plasmids. |
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 20 % |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ 1
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| SOX2 |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
|
|||
| NANOG |
Yes |
|
|
|||
| TRA 1-60 |
Yes |
|
||||
| SSEA-4 |
Yes |
|
| Marker | Present | Absent |
| mCpG | ||
| OCT4 |
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.